A Cost Analysis of the Prevention of End-stage Renal Disease

Isabelle Durand-Zaleski, Sylvie Bastuji-Garin, Stéphane Zaleski, Bertrand Weil and Guy Rostoker

Medical Decision Making, 1996, vol. 16, issue 4, 326-334

Abstract: A cost analysis was used to evaluate three possible immunoglobulin (IgG) treatment protocols for end-stage renal disease due to IgA nephropathy. The perspective chosen for the cost analysis was that of the health-care delivery system. The baseline strategy was the absence of IgG treatment, and alternative strategies corresponded to three protocols presently on trial: all three included a high initial dose of intravenous IgG. Protocol 1 followed with intramuscular IgG injections only, protocol 2 with intramuscular plus intravenous injections, and protocol 3 with intravenous injections only. The costs of treatment included the costs of immunoglobulins, outpatient hospital costs, and the costs of tests; the savings (costs averted) resulted from kidney dialysis averted. The bottom line for the health-care system is a net savings of $233,000, $213,000, or $83,000, depending on the protocol chosen. The computation of costs did not value physical and psychological health benefits. Thus, any subjective benefit, such as im proved comfort, or objective benefit, such as longer life expectancy, would be an im provement over the results presented here. Key words: cost analysis; end-stage renal disease; treatment protocols. (Med Decis Making 1996;16:326-334)

Date: 1996
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X9601600403 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:16:y:1996:i:4:p:326-334

DOI: 10.1177/0272989X9601600403

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().